New pill aims to keep leukemia at bay after initial treatment
NCT ID NCT07130695
Summary
This study is testing a drug called olutasidenib as a long-term 'maintenance' therapy for adults with a specific genetic form of acute myeloid leukemia (AML). The goal is to see if taking this pill for up to two years after finishing standard chemotherapy is safe and can help keep the cancer from coming back. Researchers will monitor 15 participants closely for side effects and to see if the treatment helps maintain remission and improve survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23298, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.